Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks’ pregnancy in normotensive women
-
Tuangsit Wataganara
,
Busadee Pratumvinit
Abstract
Introduction:
Circulating soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) are potential markers for preeclampsia. The objective was to construct and analyse the reference ranges of serum levels of sFlt-1 and PlGF throughout the course of pregnancy in low-risk Thai pregnant women.
Methods:
We enrolled 110 low-risk, Thai women singleton pregnancy from 10 to 40 gestational weeks. Serum concentrations of sFlt-1 and PlGF were measured with an automated assay. The reference ranges of serum levels of sFlt-1, PlGF and sFlt-1/PlGF ratio were constructed and assessed for possible correlations with gestational age, maternal factors [age, parity, tobacco use, artificial reproductive technologies (ARTS) and body mass index (BMI)], and pregnancy outcomes (gestational age at delivery, development of preeclampsia, neonatal birth weight and placental weight).
Results:
None of the subjects developed preeclampsia. Serum sFlt-1 concentrations significantly elevated from 20 to 40 gestational weeks (P=0.003). Significant elevation and dropping of serum PlGF levels and sFlt-1/PlGF ratios were observed at 10 to 29 and 30 to 40 weeks of gestation, respectively (P<0.001). There was an inversed correlation between serum PlGF levels at 20 to 29 gestational weeks and neonatal birth weights (r=−0.48, P<0.05). There were no associations between serum levels of sFlt-1, PlGF, or sFlt-1/PlGF ratios and maternal BMI, gestational age at delivery, or placental weight (P>0.05). Effects from parity, smoking and ARTS were inconclusive.
Conclusion:
Robust change of serum PlGF levels suggests for its broader clinical application compared to sFlt-1. Prediction of preeclampsia using serum analytes may be gestational period specific.
Acknowledgement
This study was funded by the Faculty of Medicine Siriraj Hospital. We want to thank Passara Hakularb, RN and Suchitra Pongprasobchai, RN for their assistance in the enrollment process. We also thank Suthipol Udompunthurak, MSc and Ratchaneekorn Hanyongyuth, BSc, for their technical support. The authors (T.W., B.P., and J.L.) are actively involved with another separate multicenter international study funded by Roche Diagnostics. Roche Diagnostics was not involved in design of this study, subject enrollment, quantitation of serum levels of sFlt-1 and PlGF, statistical analysis, or preparation of this manuscript.
Author’s statement
Conflict of interest: Authors state no conflict of interest.
Material and methods: Informed consent: Informed consent has been obtained from all individuals included in this study.
Ethical approval: The research related to human subject use has complied with all the relevant national regulations, and institutional policies, and is in accordance with the tenets of the Helsinki Declaration, and has been approved by the authors’ institutional review board or equivalent committee.
References
[1] Poon LC, Kametas NA, Chelemen T, Leal A, Nicolaides KH. Maternal risk factors for hypertensive disorders in pregnancy: a multivariate approach. J Hum Hypertens. 2010;24:104–10.10.1038/jhh.2009.45Search in Google Scholar PubMed
[2] Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive Value of the sFlt-1:PlGF Ratio in Women with Suspected Preeclampsia. N Engl J Med. 2016;374:13–22.10.1056/NEJMoa1414838Search in Google Scholar PubMed
[3] Cuckle HS. Screening for pre-eclampsia – lessons from aneuploidy screening. Placenta 2011;32(Suppl.):S42–8.10.1016/j.placenta.2010.07.015Search in Google Scholar PubMed
[4] LeFevre ML, Force USPST. Low-dose aspirin use for the prevention of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;161:819–26.10.7326/M14-1884Search in Google Scholar PubMed
[5] Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol. 2010;202:161 e1–11.10.1016/j.ajog.2009.09.016Search in Google Scholar PubMed
[6] Ohkuchi A, Hirashima C, Suzuki H, Takahashi K, Yoshida M, Matsubara S, et al. Evaluation of a new and automated electrochemiluminescence immunoassay for plasma sFlt-1 and PlGF levels in women with preeclampsia. Hypertens Res. 2010;33:422–7.10.1038/hr.2010.15Search in Google Scholar PubMed
[7] Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum soluble fms-like tyrosine kinase-1 in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;45:584–90.10.1002/uog.14817Search in Google Scholar PubMed
[8] Tsiakkas A, Duvdevani N, Wright A, Wright D, Nicolaides KH. Serum placental growth factor in the three trimesters of pregnancy: effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol. 2015;45:591–8.10.1002/uog.14811Search in Google Scholar PubMed
[9] O’Gorman N, Wright D, Syngelaki A, Akolekar R, Wright A, Poon LC, et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am J Obstet Gynecol. 2016;214:103e1–12.10.1016/j.ajog.2015.08.034Search in Google Scholar PubMed
[10] Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med. 2004;350:672–83.10.1056/NEJMoa031884Search in Google Scholar PubMed
[11] National Collaborating Centre for Women’s and Children’s Health (UK). Hypertension in Pregnancy: The Management of Hypertensive Disorders During Pregnancy. London, UK: RCOG Press; 2010.Search in Google Scholar
[12] Palmer KR, Tong S, Kaitu’u-Lino TJ. Placental-specific sFLT-1: role in pre-eclamptic pathophysiology and its translational possibilities for clinical prediction and diagnosis. Mol Hum Reprod. 2017;23:69–78.10.1093/molehr/gaw077Search in Google Scholar PubMed
[13] Manthati S, Pratumvinit B, Hanyongyuth R, Udompunthurak S, Phaophan A, Wataganara T. Circulating free soluble fms-like tyrosine kinase-1 during late first trimester in relation with placental volume as a surrogate for trophoblastic production: A physiology study in low-risk cohort. J Matern Fetal Neonatal Med. 2017;30:1976–83.10.1080/14767058.2016.1235697Search in Google Scholar PubMed
[14] Holston AM, Qian C, Yu KF, Epstein FH, Karumanchi SA, Levine RJ. Circulating angiogenic factors in gestational proteinuria without hypertension. Am J Obstet Gynecol. 2009;200:392e1–10.10.1016/j.ajog.2008.10.033Search in Google Scholar PubMed PubMed Central
[15] Villa PM, Hamalainen E, Maki A, Räikkönen K, Pesonen AK, Taipale P, et al. Vasoactive agents for the prediction of early- and late-onset preeclampsia in a high-risk cohort. BMC Pregnancy Childbirth. 2013;13:110.10.1186/1471-2393-13-110Search in Google Scholar PubMed PubMed Central
[16] Alahakoon TI, Zhang W, Trudinger BJ, Lee V. Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro and anti-angiogenic profiles. J Matern Fetal Neonatal Med. 2014;27:1854–9.10.3109/14767058.2014.880882Search in Google Scholar PubMed
[17] Triunfo S, Crispi F, Gratacos E, Figueras F. Prediction of delivery of small for gestational age neonates and adverse perinatal outcomes by feto-placental Doppler at 37 weeks’ gestation. Ultrasound Obstet Gynecol. 2017;49:364–71.10.1002/uog.15979Search in Google Scholar PubMed
[18] Sibai BM, Abdella TN, Anderson GD, McCubbin JH. Plasma volume determination in pregnancies complicated by chronic hypertension and intrauterine fetal demise. Obstet Gynecol. 1982;60:174–8.Search in Google Scholar PubMed
[19] Meiri H, Huppertz B, Cetin I. Development of early non-invasive markers and means for the diagnosis and progression monitoring of preeclampsia and tailoring putative therapies (project pregenesys 037244). Placenta 2011;32(Suppl.):S1–3.10.1016/j.placenta.2010.12.003Search in Google Scholar PubMed
[20] Sibiude J, Guibourdenche J, Dionne MD, Le Ray C, Anselem O, Serreau R, et al. Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction. PLoS One 2012;7:e50208.10.1371/journal.pone.0050208Search in Google Scholar PubMed PubMed Central
[21] Khalil A, Maiz N, Garcia-Mandujano R, Penco JM, Nicolaides KH. Longitudinal changes in maternal serum placental growth factor and soluble fms-like tyrosine kinase-1 in women at increased risk of pre-eclampsia. Ultrasound Obstet Gynecol. 2016;47:324–31.10.1002/uog.15750Search in Google Scholar PubMed
©2017 Walter de Gruyter GmbH, Berlin/Boston
Articles in the same Issue
- Frontmatter
- Editorial
- Preeclampsia and intrauterine growth restriction: placental disorders still not fully understood
- Review article
- Hepar uterinum: a history of ideas on fetal nutrition
- Original articles
- Twin pregnancy in women above the age of 45 years: maternal and neonatal outcomes
- Maternal endothelial damage as a disorder shared by early preeclampsia, late preeclampsia and intrauterine growth restriction
- Maternal venous SHARP1 levels in preeclampsia
- Second-trimester maternal serum markers in the prediction of preeclampsia
- Pregnancy outcomes regarding maternal serum AFP value in second trimester screening
- Quantification of mechanical dyssynchrony in growth restricted fetuses and normal controls using speckle tracking echocardiography (STE)
- Serum cholesterol acceptor capacity in intrauterine growth restricted fetuses
- Antithrombin improves the maternal and neonatal outcomes but not the angiogenic factors in extremely growth-restricted fetuses at <28 weeks of gestation
- Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy
- Fetal death: an extreme manifestation of maternal anti-fetal rejection
- Intrauterine growth restriction and placental gene expression in severe preeclampsia, comparing early-onset and late-onset forms
- The relationship between maternal and umbilical cord adropin levels with the presence and severity of preeclampsia
- Expression of placental regulatory genes is associated with fetal growth
- Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks’ pregnancy in normotensive women
- A one year review of eclampsia in an Ethiopian Tertiary Care Center (Saint Paul’s Hospital Millennium Medical College, SPHMMC)
- Congress Calendar
- Congress Calendar
Articles in the same Issue
- Frontmatter
- Editorial
- Preeclampsia and intrauterine growth restriction: placental disorders still not fully understood
- Review article
- Hepar uterinum: a history of ideas on fetal nutrition
- Original articles
- Twin pregnancy in women above the age of 45 years: maternal and neonatal outcomes
- Maternal endothelial damage as a disorder shared by early preeclampsia, late preeclampsia and intrauterine growth restriction
- Maternal venous SHARP1 levels in preeclampsia
- Second-trimester maternal serum markers in the prediction of preeclampsia
- Pregnancy outcomes regarding maternal serum AFP value in second trimester screening
- Quantification of mechanical dyssynchrony in growth restricted fetuses and normal controls using speckle tracking echocardiography (STE)
- Serum cholesterol acceptor capacity in intrauterine growth restricted fetuses
- Antithrombin improves the maternal and neonatal outcomes but not the angiogenic factors in extremely growth-restricted fetuses at <28 weeks of gestation
- Simple approach based on maternal characteristics and mean arterial pressure for the prediction of preeclampsia in the first trimester of pregnancy
- Fetal death: an extreme manifestation of maternal anti-fetal rejection
- Intrauterine growth restriction and placental gene expression in severe preeclampsia, comparing early-onset and late-onset forms
- The relationship between maternal and umbilical cord adropin levels with the presence and severity of preeclampsia
- Expression of placental regulatory genes is associated with fetal growth
- Circulating soluble fms-like tyrosine kinase-1 and placental growth factor from 10 to 40 weeks’ pregnancy in normotensive women
- A one year review of eclampsia in an Ethiopian Tertiary Care Center (Saint Paul’s Hospital Millennium Medical College, SPHMMC)
- Congress Calendar
- Congress Calendar
